New treatments for genital herpes

被引:10
作者
Snoeck, R [1 ]
De Clercq, E [1 ]
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
关键词
D O I
10.1097/00001432-200202000-00009
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
Genital herpes is a sexually transmitted disease that has been widely investigated from both an epidemiological and a diagnostic viewpoint. Better knowledge of the disease has pointed to the important role of asymptomatic herpes simplex virus type 2 shedding as a major culprit for the spread of the virus in the world, the latest statistics showing that the incidence of genital herpes is constantly increasing. The reference compound for the treatment and prophylaxis of genital herpes is acyclovir. Recently, two drugs with better oral bioavailability, valaciclovir, the oral prodrug of acyclovir, and famciclovir, the oral prodrug of penciclovir, have been made available. Nevertheless, there is a need to develop additional approaches, to extend the therapeutic possibilities and to face the problem of emerging resistant viruses, mostly in immunocompromised patients. Therefore, efforts have been made in different directions including the exploration of new targets for antiviral chemotherapy, the use of immunomodulators and the development of specific vaccines. Curr Opin Infect Dis 15:49-55. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 73 条
[1]
Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene [J].
Andrei, G ;
Snoeck, R ;
De Clercq, E ;
Esnouf, R ;
Fiten, P ;
Opdenakker, G .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :639-648
[2]
COMPARATIVE ACTIVITY OF VARIOUS COMPOUNDS AGAINST CLINICAL STRAINS OF HERPES-SIMPLEX VIRUS [J].
ANDREI, G ;
SNOECK, R ;
GOUBAU, P ;
DESMYTER, J ;
DECLERCQ, E .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (02) :143-151
[3]
Some 6-aza-5-substituted-2′-deoxyuridines show potent and selective inhibition of herpes simplex virus type 1 thymidine kinase [J].
Basnak, I ;
Sun, M ;
Hamor, TA ;
Focher, F ;
Verri, A ;
Spadari, S ;
Wroblowski, B ;
Herdewijn, P ;
Walker, RT .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 1998, 17 (1-3) :187-206
[4]
Herpes simplex virus vaccines [J].
Bernstein, DI ;
Stanberry, LR .
VACCINE, 1999, 17 (13-14) :1681-1689
[5]
Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment [J].
Bernstein, DI ;
Harrison, CJ ;
Tomai, MA ;
Miller, RL .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (06) :844-849
[6]
Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: Selection and characterization of mutant isolates [J].
Bonneau, AM ;
Kibler, P ;
White, P ;
Bousquet, C ;
Dansereau, N ;
Cordingley, MG .
JOURNAL OF VIROLOGY, 1996, 70 (02) :787-793
[7]
The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model [J].
Bourne, N ;
Bernstein, DI ;
Ireland, J ;
Sonderfan, AJ ;
Profy, AT ;
Stanberry, LR .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :203-205
[8]
Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection [J].
Bourne, N ;
Stanberry, LR ;
Kern, ER ;
Holan, G ;
Matthews, B ;
Bernstein, DI .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2471-2474
[9]
Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding [J].
Braig, S ;
Luton, D ;
Sibony, O ;
Edlinger, C ;
Boissinot, C ;
Blot, P ;
Oury, JF .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 96 (01) :55-58
[10]
Diagnosing genital ulcer disease in a clinic for sexually transmitted diseases in Amsterdam, The Netherlands [J].
Bruisten, SM ;
Cairo, I ;
Fennema, H ;
Pijl, A ;
Buimer, M ;
Peerbooms, PGH ;
Van Dyck, E ;
Meijer, A ;
Ossewaarde, JM ;
van Doornum, GJJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (02) :601-605